Silexion Therapeutics announces preclinical data on SIL204

Silexion Therapeutics (SLXN) announced new preclinical data demonstrating that subcutaneously administered SIL204 successfully reaches all primary sites of pancreatic cancer metastasis and shows anti-tumor activity. Results confirmed that SIL204 distributed to key organs where pancreatic cancer commonly spreads, with measurable reductions in tumor burden observed across multiple sites. Key Study Findings: SIL204 successfully distributed to all major metastatic sites following a single subcutaneous injection at 5mg/mouse; Reductions in bioluminescent signal, indicating decreased tumor burden, were observed at day 7 across all evaluated organs; Statistically significant reductions were achieved in the peritoneum, lung, and intestinel The liver, the most common site of pancreatic cancer metastasis, showed measurable reduction in tumor burden; Studies utilized human pancreatic cancer cells harboring the KRAS G12D mutation; The use of human equivalent dosing demonstrates that these results were achieved at drug concentrations directly relevant to planned clinical use, providing important validation for the transition from preclinical to human studies. Silexion remains on track to initiate Phase 2/3 clinical trials evaluating its dual-route administration approach in the first half of 2026, with regulatory submissions planned for Q4 2025 and Q1 2026.